• $1.25M grant-funded research partnership to transform maternity care for culturally diverse women
• Integration of HeraCARE platform to refine predictive health models and develop new AI-driven tools
• New AI models to support real-time clinical decision making and personalized maternity care

HeraMED Limited (ASX: HMD), a leading women's health technology & medical data company, has entered into a research and development partnership with RMIT University and the Digital Health Cooperative Research Centre (DHCRC). The initiative will focus on improving maternal health outcomes through the collection and use of data sets including culturally and linguistically diverse (CALD) women through AI-enabled predictive care. Under the project, titled 'AI models to assess risk of pre-term delivery linked to socio-economic factors,' HeraMED's proprietary HeraCARE platform will work with a number of health systems to onboard 200 pregnant women using HeraCARE licences to monitor and collect data through personalized care plans. The initiative will use a combination of clinical, biometric, lifestyle and genetic data, with a focus on diversity, inclusion, and clinical applicability. The project is co-funded by the DHCRC, RMIT and HeraMED, both in-kind and with cash, with an overall project value of $1,245,300. The collaboration will involve diverse data integration, enhancing the RMIT-based Pregnancy Knowledge Base, supporting real-time remote monitoring through HeraCARE, developing new advanced AI models to provide real-time risk insights and adaptive treatment pathways, and aligning with global efforts to improve genomic inclusivity. The project is scheduled to commence in the second quarter of 2025, with key deliverables including a validated AI model, clinical decision-support tool, and regulatory pathway mapping for scaled commercial rollout.

The project is expected to generate a trained AI predictive model, which will be commercialized under licensed IP between HeraMED and RMIT/DHCRC. HeraMED's cash contribution to the 18-month project will be approximately $250,000.

The collaboration will advance HeraMED's 'data-as-an-asset' and commercialization strategy, with the HeraCARE platform expected to be enhanced with the integration of advanced AI models, which can be monetized via subscription-based models, licensing, and integration with third-party health systems.